Sutro Biopharma Inc
NASDAQ:STRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sutro Biopharma Inc
Additional Paid In Capital
Sutro Biopharma Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sutro Biopharma Inc
NASDAQ:STRO
|
Additional Paid In Capital
$845.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$22.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$8.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
35%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$14B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
Sutro Biopharma Inc
Glance View
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
See Also
What is Sutro Biopharma Inc's Additional Paid In Capital?
Additional Paid In Capital
845.5m
USD
Based on the financial report for Dec 31, 2025, Sutro Biopharma Inc's Additional Paid In Capital amounts to 845.5m USD.
What is Sutro Biopharma Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
9%
Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Sutro Biopharma Inc have been 8% over the past three years , 9% over the past five years .
